Phase I study of ribociclib (CDK4/6 inhibitor) with spartalizumab (PD-1 inhibitor) with and without fulvestrant in metastatic hormone receptor-positive breast cancer or advanced ovarian cancer
Details
Publication Year 2025-02-25,Volume 13,Issue #2,Page e010430
Journal Title
Journal for Immunotherapy of Cancer
Publication Type
Research article
Abstract
BACKGROUND: Preclinical evidence suggests that cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors enhance antitumor immunity. We conducted a phase I trial of ribociclib (CDK4/6 inhibitor) plus spartalizumab (PD-1 inhibitor) in patients with hormone receptor (HR)-positive/HER2-negative metastatic breast cancer (MBC) or advanced ovarian cancer (AOC). The combination was also evaluated with fulvestrant in MBC. METHODS: In Cohort A, ribociclib was administered on Days 1-21 (28-day cycle) starting at 400 mg, and spartalizumab at 400 mg on Day 1. Dose escalation was followed by expansion in AOC. Fulvestrant was added (Cohort B) with a safety run-in followed by expansion in MBC. Primary objectives were to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), and safety and tolerability of the combinations. RESULTS: 33 patients enrolled (n=18, Cohort A; n=15, Cohort B). The RP2D of ribociclib in both cohorts was 600 mg. Treatment-related adverse events in >20% of patients in either cohort were neutropenia, fatigue, anemia, thrombocytopenia, hypertransaminasemia, maculopapular rash, fatigue, and nausea. Hypertransaminasemia occurred in 66.7% (AST) and 46.7% (ALT) of patients in Cohort B, including 46.7% and 40.0%, respectively, of grade 3 or 4 events. Two confirmed partial responses were observed (13.3%) in Cohort B, in patients with low baseline serum thymidine kinase activity, coupled with an increase on-treatment. Peripheral blood flow cytometry across patients demonstrated on-target drug binding with increases in PD-1 occupancy and activated CD8(+) T cells during treatment, irrespective of response. PD-L1-positivity, tumor-infiltrating lymphocytes, or tumor mutational burden did not correlate with progression-free survival (PFS). Several copy-number variations detected with next-generation sequencing correlated with PFS. CONCLUSIONS: Ribociclib with spartalizumab and fulvestrant showed limited efficacy and elevated hepatotoxicity, precluding further development. Correlative analyses revealed treatment-induced immunological effects, and genomic alterations associated with PFS.
Publisher
BMJ
Keywords
Humans; Female; *Purines/therapeutic use/pharmacology/administration & dosage; *Breast Neoplasms/drug therapy/pathology; Middle Aged; *Antineoplastic Combined Chemotherapy Protocols/therapeutic use/adverse; effects/pharmacology; *Ovarian Neoplasms/drug therapy; Aged; *Aminopyridines/therapeutic use/administration & dosage/pharmacology; Adult; *Fulvestrant/therapeutic use/administration & dosage; *Antibodies, Monoclonal, Humanized/therapeutic use/administration &; dosage/adverse effects/pharmacology; Receptors, Estrogen/metabolism; Aged, 80 and over; Neoplasm Metastasis; Breast Cancer; Immunotherapy; Ovarian Cancer
Department(s)
Medical Oncology
Open Access at Publisher's Site
https://doi.org/10.1136/jitc-2024-010430
Terms of Use/Rights Notice
Refer to copyright notice on published article.


Creation Date: 2025-03-18 06:23:42
Last Modified: 2025-03-18 06:24:11

© 2025 The Walter and Eliza Hall Institute of Medical Research. Access to this website is subject to our Privacy Policy and Terms of Use

An error has occurred. This application may no longer respond until reloaded. Reload 🗙